<DOC>
	<DOCNO>NCT00257673</DOCNO>
	<brief_summary>The purpose study determine 12-week treatment study MEM 1003 safe effective treatment patient mild moderate Alzheimer 's disease .</brief_summary>
	<brief_title>Safety Efficacy MEM 1003 Versus Placebo Patients With Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>Alzheimer 's disease lead cause dementia one common diseases age population . It chronic brain disease involve gradual memory loss , decline ability perform routine task , disorientation , difficulty learning , loss language skill , impairment judgment , personality change affect individual . The neurodegenerative nature disease eventually lead failure organ system death . Perturbations calcium homeostasis central nervous system , associate Alzheimer 's disease age well stroke head trauma result increase intracellular level calcium ( Ca2+ ) . Increased level Ca2+ may lead cellular dysregulation cell death . The role calcium neurodegenerative process lead hypothesis control calcium level may beneficial , particularly progressive neuronal damage result cognitive dysfunction memory loss . MEM 1003 ( + ) -enantiomer dihydropyridine optimized central nervous system activity . It inhibit L-type Ca2+ channel within anticipated human dose range benign cardiovascular effect DHP L-Type calcium channel modulators .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>standardize MMSE Score 10 24 point diagnosis probable Alzheimer 's disease magnetic resonance imaging compute tomography examination compatible AD modify Hachinski Ischemia Score less equal 4 currently receive AD therapy currently receive donepezil , rivastigmine , galantamine Exclusion criterion : head injury associate cognitive impairment history vascular dementia stroke , transient cerebral ischemic episode , major depression , major psychotic disorder , symptomatic postural hypotension treatment Alzheimer 's disease donepezil , rivastigmine , galantamine ; tacrine permit last 30 day memantine last 90 day treatment calcium channel blocker investigational medication within prior 30 day</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Cognition</keyword>
	<keyword>Alzheimer 's</keyword>
	<keyword>Cognitive impairment</keyword>
</DOC>